Treating asymptomatic patients with severe aortic stenosis using TAVR or SAVR leads to better survival and lower healthcare costs, according to new data presented at EuroPCR. Researchers analyzed over 24,000 U.S. cases and found patients treated before symptom onset had significantly reduced one-year costs—$146K vs. $182K for those with acute symptoms—and fewer hospitalizations.
Mortality was more than 7x higher in patients treated late. Asymptomatic patients also saw shorter hospital stays and fewer complications. The findings further support the FDA’s recent approval of Edwards’ Sapien 3 valve for treating asymptomatic aortic stenosis.
Follow MEDWIRE.AI for insights on cardiac device innovation.
